Skip to main content

Advertisement

SpringerLink
Log in

Multi-Targeted Tyrosine Kinase Inhibitor-Induced Hyperammonemic Encephalopathy: a Report of Two Cases Using Pazopanib, Sunitinib, and Regorafenib

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin. 2013;63(4):249–79. https://doi.org/10.3322/caac.21184.

    Article  PubMed  Google Scholar 

  2. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12. https://doi.org/10.1016/S0140-6736(12)61900-X.

    Article  CAS  Google Scholar 

  3. Demetri GD, Reichardt P, Kang Y-K, Blay J-Y, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295–302. https://doi.org/10.1016/S0140-6736(12)61857-1.

    Article  CAS  PubMed  Google Scholar 

  4. Nott L, Price TJ, Pittman K, Patterson K, Fletcher J. Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy. Leuk Lymphoma. 2007;48(9):1702–11. https://doi.org/10.1080/10428190701509822.

    Article  CAS  PubMed  Google Scholar 

  5. Liaw C-C, Wang H-M, Wang C-H, Yang T-S, Chen J-S, Chang H-K, et al. Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. Anti-Cancer Drugs. 1999;10(3):275–81. https://doi.org/10.1097/00001813-199903000-00004.

    Article  CAS  PubMed  Google Scholar 

  6. Lee N-R, Yhim H-Y, Yim C-Y, Kwak J-Y, Song E-K. Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors. Ann Pharmacother. 2011;45(10):e56. https://doi.org/10.1345/aph.1Q038.

    Article  PubMed  Google Scholar 

  7. Shea Y-F, Chiu W, Mok M, Yau C. Sunitinib-induced hyperammonaemia in a patient with pancreatic neuroendocrine tumour. J Clin Pharm Ther. 2013;38(4):327–9. https://doi.org/10.1111/jcpt.12054.

    Article  CAS  PubMed  Google Scholar 

  8. Pilanc KN, Elbüken F, Ordu Ç, Köksal G, Tekelioglu MH, Okutur K, et al. A rare case of sunitinib-induced hyperammonemic encephalopathy and hypothyroidism in metastatic renal cell carcinoma. Am J Ther. 2016;23(2):e583–7. https://doi.org/10.1097/MJT.0b013e3182a32e0e.

    Article  PubMed  Google Scholar 

  9. Brandi G, Rosa F, Calzà L, Girolamo SD, Tufoni M, Ricci CS, et al. Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients? Liver Int. 2013;33(3):488–93. https://doi.org/10.1111/liv.12102.

    Article  PubMed  Google Scholar 

  10. Kuo JC, Parakh S, Yip D. Regorafenib-induced hyperammonemic encephalopathy. J Clin Pharm Ther. 2014;39(4):446–8. https://doi.org/10.1111/jcpt.12160.

    Article  CAS  PubMed  Google Scholar 

  11. Kitamoto H, Satake H, Hatachi Y, Tetsuro I, Akihito T. Regorafenib-induced hyperammonemic encephalopathy in metastatic colon cancer. J Cancer Prev Curr Res. 2015;3(2):1–4.

    Google Scholar 

  12. Willson KJ, Nott LM, Broadbridge VT, Price T. Hepatic encephalopathy associated with cancer or anticancer therapy. Gastrointest Cancer Res. 2013;6(1):11–6.

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Tanapon Boonchuaysream for English editing and grammatical corrections. NN acknowledges the Talent Management Program, Mahidol University and the Ramathibodi Grant for Research Development, Ramathibodi Hospital.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

    Noppadon Kongsuphon, Noramon Teeraaumpornpunt & Jitprapa Konmun

  2. Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

    Maturos Soukavanitch, Touch Ativitavas & Nuttapong Ngamphaiboon

Authors
  1. Noppadon Kongsuphon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maturos Soukavanitch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Noramon Teeraaumpornpunt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jitprapa Konmun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Touch Ativitavas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nuttapong Ngamphaiboon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nuttapong Ngamphaiboon.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kongsuphon, N., Soukavanitch, M., Teeraaumpornpunt, N. et al. Multi-Targeted Tyrosine Kinase Inhibitor-Induced Hyperammonemic Encephalopathy: a Report of Two Cases Using Pazopanib, Sunitinib, and Regorafenib. J Gastrointest Canc 50, 601–603 (2019). https://doi.org/10.1007/s12029-018-0067-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-018-0067-6

Keywords

Search

Navigation